Kalorama: White House Precision Medicine Initiative Spotlights Tissue Diagnostics
NEW YORK, Feb. 20, 2015 /PRNewswire/ -- Kalorama Information says the 'Precision Medicine Initiative announced by the White House as part of its 2016 budget could provide a boost to the tissue diagnostics and cell-based diagnostics industry. The healthcare market research publisher notes that the initiative is combined with real funding, as part of a $215 million investment in the President's 2016 Budget, the Precision Medicine Initiative is aimed at promoting "patient-powered research" that "promises to accelerate biomedical discoveries and provide clinicians with new tools, knowledge, and therapies to select which treatments will work best for which patients." Those discoveries will be facilitated through tissue and cell diagnostics, according to Kalorama. Kalorama completely covered the tissue diagnostics (histology) and cell-based (cytology) industry in its recent report, The World Market for Tissue Diagnostics and Cell-Based Diagnostics. (http://www.kaloramainformation.com/Tissue-Cell-Based-8540184/)
"Any program that focuses attention on precision medicine is going to be good news for histology and cytology testing," said Bruce Carlson, Publisher of Kalorama Information. "These type of tests are the main pathway to individual testing."
Tissue diagnostics include in situ hybridization and immunohistochemistry, important tests for determining drug efficacy and disease progress. Driven by new technologies and the need to discover biomarkers, the tissue and cell-based diagnostic market grew to an estimated 7.4 billion in revenues in 2013 for in vitro diagnostic (IVD) and other reagents used by clinical laboratories, according to Kalorama Information, according to Kalorama's Report. The once field is increasingly automated and many new technologies are now being applied in this field, including mass spectrometry, DNA sequencing, circulating tumor cells, and others.
The White House's announcement said that while most treatments are designed for the "average patient." And precision medicine can be an innovative approach to disease prevention and treatment that takes into account individual differences in people's genes, environments, and lifestyles. Precision medicine gives clinicians tools to better understand the complex mechanisms underlying a patient's health, disease, or condition, and to better predict which treatments will be most effective. Funding proposals in the President's budget include:
- $130 million to NIH for development of a voluntary national research cohort of a million or more volunteers to propel our understanding of health and disease and set the foundation for a new way of doing research through engaged participants and open, responsible data sharing.
- $70 million to the National Cancer Institute (NCI), part of NIH, to scale up efforts to identify genomic drivers in cancer and apply that knowledge in the development of more effective approaches to cancer treatment.
- $10 million to FDA to acquire additional expertise and advance the development of high quality, curated databases to support the regulatory structure needed to advance innovation in precision medicine and protect public health.
- $5 million to ONC to support the development of interoperability standards and requirements that address privacy and enable secure exchange of data across systems.
"Patients with breast, lung, and colorectal cancers, as well as melanomas and leukemias, for instance, routinely undergo molecular testing as part of patient care, enabling physicians to select treatments that improve chances of survival and reduce exposure to adverse effects," the White House statement said.
The report, The World Market for Tissue Diagnostics and Cell-Based Diagnostics, contains more trends in the histology and cytology test industries, including breakouts of important segments in cytology and histology testing, as well as profiling scores of companies in the market. Geographic breakdowns of the market are also provided. The report can be obtained at http://www.kaloramainformation.com/Tissue-Cell-Based-8540184/
About Kalorama Information
Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog at www.kaloramainformation.com.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
www.KaloramaInformation.com
SOURCE Kalorama Information
Share this article